Fenofibrate, Statins, and Inflammation
To the Editor:
I recently read the review by Berg et al, about tissue, inflammation, and cardiovascular disease.1 Although the review discusses our research on ligands for peroxisome proliferator activated receptor (PPAR), we used fenofibrate, a PPAR-α activator, not glitazones, PPAR-γ agonists, as the review suggests.2 We also found that statins non-significantly lower serum adiponectin levels, not as the review states that statins marginally increase adiponectin levels.3
Berg AH, Scherer PE. Adipose tissue, inflammation, and cardiovascular disease. Circ Res. 2005; 96: 939–949.
Koh KK, Quon MJ, Han SH, Chung WJ, Ahn JY, Seo YH, Kang MH, Ahn TH, Choi IS, Shin EK. Additive beneficial effects of losartan combined with simvastatin in the treatment of hypercholesterolemic, hypertensive patients. Circulation. 2004; 110: 3687–3692.